HEP 114

Drug Profile

HEP 114

Alternative Names: HEP-114

Latest Information Update: 12 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator TGV-Laboratories
  • Class
  • Mechanism of Action Lipid peroxidation inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Liver disorders

Most Recent Events

  • 12 Aug 2017 HEP 114 is still in phase III trials for Liver disorders in Russia (IV) (TGV-Laboratories Pipeline, August 2017)
  • 12 Aug 2017 Preclinical feasibility studies are ongoing in USA (PO, IV) (TGV-Laboratories Pipeline, August 2017)
  • 20 Jan 2016 TGV-Laboratories completes a phase III trial in Liver disorders in Russia (PO) before January 2016 (TGV-Laboratories Pipeline, January 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top